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ABSTRACT
Background: The human IL1RL1ST2 gene encodes IL33 receptor. Recently, IL33 has been recognized as a
key molecule for the development of Th2 response. Although mast cells and basophils are major targets of IL33
and play important roles in IL33-mediated Th2-type immune responses, the expression mechanism of ST2 in
mast cells and basophils is largely unknown. In the present study, we analyzed regulation mechanism of the
human ST2 promoter in the human mast cell line LAD2 and basophilic cell line KU812.
Methods: Promoter activity was determined by reporter assay with plasmids carrying the wild-type ST2 pro-
moter obtained from human genomic DNA and its mutant. The transcription factor binding to the identified cis-
element was identified by an electrophoretic mobility shift assay (EMSA). The effect of candidate transcription
factor on ST2 expression was confirmed by analyzing ST2 mRNA level in siRNA-introduced cells.
Results: Reporter assay demonstrated that a cis-element of typical Ets-family binding sequence was critical
for promoter activity in LAD2 and KU812. An Ets-family transcription factor PU.1 bound to this element in
an EMSA. When PU.1 expression was suppressed by siRNA, ST2 mRNA level was significantly reduced in
KU812.
Conclusions: These observations indicated that PU.1 positively regulates the ST2 promoter as a transcription
factor that directly transactivates the ST2 promoter via Ets-family-related cis-element in mast cells and baso-
phils.
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INTRODUCTION
IL33, which was identified as a ligand for IL1RL1ST2
in 2005,1 is expressed in various cell types including
fibroblasts, epithelial cells, and endothelial cells with
localization in the nucleus in a steady state.2 IL33 is
released upon cell lysis following pro-inflammatory
stimulation and causes Th2-type immune responses
through binding to IL1RL1ST2. Several studies have
demonstrated that not only Th2 but also mast cells
and basophils are key target cells of IL33.3-8
The human IL1RL1ST gene is constitutively
transactivated in mast cellsbasophils and the tran-
script is mainly driven from the distal promoter in
mast cellsbasophils, whereas another proximal pro-
moter at 10.5 kb downstream is activated in fibro-
blasts.9,10 In previous studies, a transcription factor,
GATA1, transactivated the ST2 distal promoter via
GATA-motifs in this region in mouse mast cells,10
whereas another GATA-family transcription factor
GATA3 transactivated the same promoter in mouse T
cells.11 In contrast, another transcription factor PU.1
belonging to the Ets-family regulates mast cell
basophil-specific gene regulation in a synergistic
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manner with GATA12.12,13 However, the involve-
ment of PU.1 in the human ST2 promoter is largely
unknown. These observations prompted us to ana-
lyze the role of PU.1 in the regulation of the human
ST2 promoter.
METHODS
CELLS
Human mast cell leukemia, LAD2, which was kindly
provided by Dr. Arnold Kirshenbaum,14 and human
basophilic leukemia, KU812, were maintained as de-
scribed previously.12,15 This study was approved by
the ethics committee of Juntendo University School
of Medicine.
PLASMIDS
The human IL1RL1ST2 gene promoter was ampli-
fied by PCR using the following primers and human
genomic DNA purified from peripheral blood using a
QIAamp DNA Blood Midi Kit (QIAGEN, Hilden, Ger-
many) as template. Synthesized oligonucleotides 5’-C
AAATAGGGAGAATcTcGaGAAAACTGCAGTTAAC-
3’ (nucleotide replacement and introduced XhoI sites
are shown with lower-case letters and italic, respec-
tively) and 5’-ccaagcTTCTGCCCACAGTTTCACAAC
TCAGAAAGCCA-3’ (nucleotide replacement and in-
troduced HindIII sites are shown with lower-case let-
ters and italic, respectively) were used as forward and
reverse primers, respectively, to obtain -100+84. Am-
plified DNA was inserted into a reporter plasmid,
pGL4-Basic (Promega, Madison, WI, USA) after di-
gestion with appropriate restriction endonucleases. A
mutant reporter plasmid lacking Ets-sequence was
generated using a QuikChange II site-directed
mutagenesis kit (Stratagene, La Jolla, CA, USA) with
5 ’ -CAGCTTATCAGTAACCTGGTTaacGTCTCTTAA
CTG-3’ (nucleotide replacements are shown with
lower-case letters). All nucleotide sequences of in-
serted DNA were confirmed by sequencing analysis.
The expression plasmids, pCR-PU.112 and pCR-
GATA2,16 were generated in our previous study.
REPORTER ASSAY
Each reporter plasmid (5 μg) and an internal control
plasmid pRL-null (25 ng; Promega), or reporter plas-
mid (5 μg) and co-expression plasmid (totally 6 μg)
were introduced into LAD2 and KU812 by electropo-
ration using Genepulser II (BioRad Laboratories,
Hercules, CA, USA). At 20-24 h after transfection,
cells were harvested and relative luciferase activity in
cells was determined using a luminometer, Micro
Lumat Plus (Berthold Technologies, Bad Wildbad,
Germany) with a Dual-luciferase assay kit (Promega)
as described previously.12,17
ELECTROPHORETIC MOBILITY SHIFT ASSAY
(EMSA)
The synthesized oligonucleotide 5’-GTAACCTGGTT
CCTGTCTCTTAAC-3’ (-48-25 of the ST2 promoter)
and an oligonucleotide complementary to it were 5’-
FITC-labeled and were annealed to obtain double-
stranded probe DNA. Nuclear extract was prepared
from KU812 cells according to a previously reported
method18 with some modifications. Briefly, 1 × 107
cells were suspended in 500 μl of Buffer A (10 mM
HEPES-KOH pH7.9, 1.5 mM MgCl2, 10 mM KCl, 1
mM DTT) and kept on ice for 30 min. The suspended
cells were then passed through 30 G needles 30
times. After centrifugation at 700 x g for 10 min, the
pellet was resuspended in 100 μl of Buffer B (20 mM
HEPES-KOH pH7.9, 25% glycerol, 450 mM NaCl, 1.5
mM MgCl2, 1 mM DTT). A Halt Protease Inhibitor
Cocktail Kit (PIERCE, Rockford, IL, USA) was con-
tained in both Buffer A and Buffer B. PU.1 protein
was produced using a TNT T7 quick-coupled tran-
scriptiontranslation system with pCR-PU.1 as tem-
plate. Wild-type competitor (same sequence as the
probe DNA), and mutant Ets competitor (5’-
GTAACCTGGTctCTGTCTCTTAAC-3’, mutated nu-
cleotides are shown with lower-case letters) were
used in competition assay. Electrophoresis of probe-
protein mixture and detection of fluorescence were
performed as described previously.19-21
INTRODUCTION OF SMALL INTERFERING (si)
RNA
Ten microliters of 20 μM PU.1 siRNA (Stealth Select
RNAi, #HSS144058, Invitrogen, Carlsbad, CA, USA)
or control siRNA (Stealth RNAi Negative Universal
Control, #46-2000, Invitrogen) was introduced to 2 ×
106 cells with a Neon 100 μl kit using an electropora-
tor, Neon transfection system (Invitrogen), set at pro-
gram #16. The transfection efficiency of this condition
was confirmed to be over 98% by monitoring BLOCK-
iT Alexa Fluor Red Fluorescent Oligo (#14750-100,
Invitrogen) using flow cytometry.
QUANTIFICATION OF mRNA
Total RNA was prepared from LAD2 and KU812 us-
ing an RNeasy Micro Kit (QIAGEN) and was reverse
transcribed with a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City,
CA, USA). Quantification of ST2 mRNA and PU.1
mRNA was performed using TaqMan system with
TaqMan Gene Expression Assays (Applied Bio-
systems; #Hs00545033_m1 for IL1RL1ST2, and
#Hs02786711_m1 for Spi1PU.1) with human
GAPDH #4326317E as a housekeeping gene.
RESULTS
AN Ets-MOTIF IN THE HUMAN ST2 PROMOTER
IS INVOLVED IN TRANSCRIPTION ACTIVITY
In the previous studies, the essential region of the he-
matopoietic cell-specific distal promoter was identi-
fied to be located approximately 100 bp from the tran-
scription start site, and two GATA-motifs in this re-
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Fig.　1　Transcription activity of the human ST2 promoter in LAD2 and KU812. (A) Nucleotide sequence of the 
human ST2 gene around the hematopoietic cell-specifi c distal promoter. The transcription start site determined 
by 5’-RACE in a previous study is expressed as +1.9 Upper-case and lower-case letters represent the sequences 
in exon and in the promoter, respectively. A typical Ets-motif in the human ST2 gene is boxed and putative 
GATA-binding cis-elements previously identifi ed in the mouse ST2 gene 10, 11 are underlined. (B) Relative lucifer-
ase activity is displayed as the ratio of luciferase activity versus that in pGL4-Basic transfectant. Data represent 
means ± SEM of six independent experiments performed with triplicate samples. Open bar, pGL4-Basic; closed 
bar, wild type ST2 promoter; dotted bar, mutant ST2 promoter lacking an Ets-motif. *p < 0.05, **p < 0.01 in two-
tailed paired Student’s t test.
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gion were identified to be cis-elements critical for pro-
moter function.10,11 As shown in Fig. 1A, a typical Ets-
motif is located in the minimized promoter region
close to a GATA-motif, at -39-36, and this Ets-motif is
conserved between human and mouse. We evaluated
the effect of this Ets-motif on promoter activity by a
reporter assay. The human ST2 promoter -100+84
exhibited significantly higher transcription activity
than promoter-less pGL4-Basic (Fig. 1B) and the
+16+84 region (data not shown) in human mast leu-
kemia cell line LAD2 and human basophilic cell line
KU812. Nucleotide replacement at this Ets-motif
caused significant reduction of promoter activity in
both cell lines (ΔEts in Fig. 1B). This result demon-
strates that an Ets-motif at -39-36 is involved in the
transcription activity of the human ST2 promoter in
LAD2 and KU812.
THE BINDING OF AN Ets-FAMILY TRANSCRIP-
TION FACTOR PU.1 TO THE Ets-MOTIF
To determine the transcription factor(s) binding to
the cis-element at -39-36, EMSA was performed us-
ing double-stranded DNA at -48-25 of the ST2 pro-
moter as a probe. When nuclear proteins extracted
from KU812 cells were added, several shift bands
with lower mobility than that of free probe appeared
(Fig. 2A, lane 3). The density of a major band was re-
duced in the presence of anti-PU.1 Ab (Fig. 2A, lane
1, shown with an arrowhead), whereas Ab against
Spi-B, which is another Ets-family protein, did not af-
fect this band intensity (Fig. 2A, lane 2). The most
pronounced band in the mixture of the probe and
PU.1 protein that was synthesized with the in vitro
transcriptiontranslation system completely disap-
peared upon addition of anti-PU.1 Ab but not by anti-
Spi-B Ab (Fig. 2A, lanes 4, 5, and 6). The mobility of
the complex with the probe and in vitro translated
PU.1 was slightly lower than that of the complex with
nuclear PU.1. The difference of the mobility is likely
to have been due to the fusion of Flag-tag at the N-
terminus of PU.1, resulting in the higher molecular
weight of in vitro translated PU.1. Regardless of the
slight difference of mobility shift, these results sug-
gest that PU.1 binds to the ST2 promoter region
around the cis-element in vitro. EMSAs were per-
formed with competitive oligonucleotides to further
confirm whether PU.1 specifically binds to the probe
DNA via a core sequence at -39-36 (Fig. 2B). The
specific band shift, which disappeared upon addition
of anti-PU.1 Ab (Fig. 2B, lane 2), was retained by ad-
dition of the mutant competitor lacking Ets-motif,
mEts (Fig. 2B, lane 4), whereas the specific band dis-
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Fig.　2　PU.1 binds to -48/-25 of the human ST2 promoter in vitro. (A) EMSA profi le with a probe of -48/-25 and proteins in 
the presence or absence of Ab. Nuclear extract, nuclear proteins from KU812 cells; in vitro PU.1, in vitro transcription/trans-
lation reaction mixture with PU.1 expression plasmid; -, without Ab; PU.1, with anti-PU.1 Ab; Spi-B, with anti-Spi-B Ab. The 
specifi c band of complex with PU.1 and a probe is marked with an arrowhead. Competition assay using in vitro translated 
PU.1 (B) or KU812 nuclear extract (C). mEts, oligonucleotide containing mutated Ets site (nucleotide sequence is shown in 
Methods); self, competitive oligonucleotide with wild-type sequence.
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appeared in the presence of wild-type competitor
(Fig. 2B, lane 3). When the mutant probe with same
sequence as mEts was used instead of wild-type
probe, the specific band was not detected (Fig. 2B,
lane 5). Similarly, when competition assay was per-
formed with KU812 nuclear proteins, the specific
band with PU.1 was still detected in the presence of
mEts competitor (Fig. 2C, lane 3), whereas this band
and all other bands disappeared in the presence of
wild-type competitor (Fig. 2C, lane 2). The band
(shown with an asterisk) showing lower mobility than
that of the band containing PU.1 (shown with an ar-
rowhead) was also detected when mEts was used as
competitor (Fig. 2C, lane 3), suggesting that another
protein may bind the core sequence as well as PU.1.
Taken together, these results demonstrate that PU.1
binds to the ST2 promoter region via a core sequence
at -39-36.
ST2 PROMOTER TRANSACTIVATION ACTIVITY
OF PU.1
In order to evaluate the effect of PU.1 on ST2 pro-
moter activity, co-expression reporter analysis was
performed using KU812. The presence of exogenous
PU.1 increased ST2 promoter activity, whereas pGL4-
Basic was not affected by PU.1 co-expression (Fig. 3).
The presence of both binding elements for PU.1
and GATA has been found in mast cell-specific enhan-
cer regions.12,22 PU.1 and GATA12 cooperate in
mast cells,12,13 in contrast, PU.1 and GATA12 inhibit
each other in other hematopoietic lineages.23-26 Then,
the effects of PU.1 and GATA2 on the human ST2
promoter were analyzed to confirm whether the ST2
promoter is one of the models of this cooperation sys-
tem. As shown in Figure 3, co-expression of PU.1 and
GATA2 caused significantly higher transcription ac-
tivity of the ST2 promoter compared with co-
expression of PU.1 alone.
Role of PU.1 in the Human IL1RL1ST2 Promoter
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Fig.　3　PU.1 and GATA2 cooperatively transactivates the human ST2 pro-
moter. Relative luciferase activity is displayed as the ratio of luciferase ac-
tivity versus that in pGL4-Basic and mock transfectant. Data represent 
means ± SD of triplicate samples. The total amount of co-expression plas-
mid was adjusted to 6 μg as follows: m, 6 μg mock vector (pCR3.1); P, 3 
μg pCR-PU.1 and 3 μg pCR3.1; P + G, 3 μg pCR-PU.1 and 3 μg pCR-
GATA2. ns, not signifi cant. *p < 0.05.
0 10 20 30 40
m
P
P + G
m
P
P + G
Relative luciferase activity  
pGL4-Basic
pGL4-ST2 WT
*
ns
ns
*
Fig.　4　Effect of PU.1 knockdown on ST2 expression. The 
mRNA expression levels of PU.1 (top) and ST2 (bottom) in 
PU.1 siRNA transfectants (open bar) are shown as the ratio 
of mRNA levels vs. that in control siRNA transfectants 
(closed bar). Data represent means ± SD of six transfec-
tants, each of which was analyzed by real-time PCR of tripli-
cate samples. *p < 0.05; **p < 0.01 in two-tailed unpaired 
Student’s t test.
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EFFECT OF PU.1 siRNA ON ST2 EXPRESSION
To examine the involvement of PU.1 in ST2 expres-
sion, the expression of PU.1 was knocked down by
siRNA. By the detection of red fluorescent oligonu-
cleotides, which were introduced by electroporation
using a Neon system, the transfection efficiency in
KU812 was confirmed to be over 98% (data not
shown). When PU.1 siRNA was introduced in KU812
under the same conditions, PU.1 mRNA level was re-
duced by 90% at 24 h after transfection and the reduc-
tion was continued until at least 72 h (Fig. 4, top). In
these conditions, the amount of ST2 mRNA was sig-
nificantly lower than that in control siRNA transfec-
tants (Fig. 4, bottom). These results indicate that
PU.1 participates in expression of ST2.
DISCUSSION
IL33 receptor is encoded by the human IL1RL1ST2
gene that possesses two promoters, the distal pro-
moter for hematopoietic lineages and the proximal
promoter for non-hematopoietic lineages.9,10 Among
hematopoietic lineages known as the target of IL33,
mast cells and basophils play important roles in IL33-
mediated Th2-type immune responses. In previous
studies regarding the transcriptional regulation
mechanism of the mouse ST2 promoter, two GATA-
motifs in the distal promoter were identified to be
critical cis-elements, which were recognized with
GATA1 in mouse mast cells10 and with GATA3 in
mouse T cells.11 However, when nucleotide se-
quences of the ST2 promoters were compared be-
tween human and mouse, transcription start site of
the human ST2 gene was shown to be located ap-
proximately 60 bp upstream compared with that of
mouse and the sequence around a GATA-motif at 5’-
Baba Y et al.
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site was highly conserved containing a typical Ets-
motif, but another GATA-motif was absent (Fig. 1A).
In the present study, the involvement of this Ets-motif
in promoter function was examined, because we have
previously found that the Ets-motif close to the
GATA-motif exhibited mast cellbasophil-specific en-
hancing activity mediated by PU.1.12
A mutant promoter carrying nucleotide replace-
ment in the Ets-motif at -39-36 showed significantly
reduced transcriptional activity compared with the
wild-type ST2 promoter in LAD2 and KU812 (Fig. 1).
Among several bands in EMSA using nuclear extract
from KU812, a major band was identified to represent
a complex of probe and PU.1 (Fig. 2). In addition, ex-
ogenous expression of PU.1 transactivated the ST2
promoter (Fig. 3). These results suggest that an Ets-
motif at -39-36 is critical for the ST2 promoter and
that PU.1 is one of the candidates transactivating the
ST2 promoter via this Ets-motif. Finally, PU.1 knock-
down by siRNA resulted in suppression of ST2 ex-
pression in KU812 (Fig. 4). From these results, it is
concluded that PU.1 transactivates the human ST2
promoter via binding to an Ets-motif at -39-36 in
these lineages.
Although we have tried to identify other transcrip-
tion factor(s) that bind to a critical element at -39-36
in EMSA using Abs against various transcription fac-
tors, no additional specific disappearance of bands
has been observed so far. Further experiments to
identify the transcription factor(s) that bind to the ele-
ment at -39-36 will be required to reveal the mecha-
nism of ST2 expression in mast cells and basophils.
Regardless, we demonstrated that a cis-element at
-39-36 is critical for ST2 promoter activity and that
PU.1 is involved in ST2 expression in the present
study.
We have previously reported that PU.1 is involved
in transcription of the human FcεRI α gene.12 Re-
cently, we introduced PU.1 siRNA into LAD2 to con-
firm our previous findings by using the up-to-date ex-
perimental technologies, and we found that PU.1
knock down reduced the cell expression of FcεRI
(Inage, E., unpublished data). Therefore, PU.1 knock
down may exhibit anti-allergic effects by suppressing
multiple pathways in mast cellsbasophils including
IL33- and IgE-mediated activation signaling.
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